Ifm_05-may - 2022

Research published around May 2022 explored the impact of "early" vs. "late" discontinuation (stopping before or after 3 years), noting that early stopping is often forced by toxicity rather than choice.

If you are looking for guidance based on this study's results:

Early versus Late Discontinuation of Maintenance Therapy in ... - MDPI IFM_05-May 2022

The study demonstrated a clear overall survival benefit for patients receiving maintenance therapy compared to a placebo.

The (often referred to simply as the IFM-05 study) focused on using lenalidomide as a maintenance treatment. Research published around May 2022 explored the impact

Due to the risk of secondary cancers identified in the IFM-05 trial, long-term monitoring for new symptoms or blood changes is standard practice for those on this regimen.

One critical finding was an increased risk of developing a second primary malignancy (SPM) while on long-term lenalidomide maintenance. Patient Considerations - MDPI The study demonstrated a clear overall

A significant number of patients (roughly 27%) had to stop the maintenance therapy early due to adverse side effects.